← All trials
NCT00640263
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2009
- Primary completion
- May 1, 2013
- Completion date
- Feb 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 1500
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- French National Agency for Research on AIDS and Viral HepatitisLead sponsor
- East London Hospital ComplexOverall official - principal investigator
- University of OuagadougouOverall official - principal investigator
- University of ZambiaOverall official - principal investigator
- Makerere UniversityOverall official - principal investigator
- Uppsala UniversityOverall official - principal investigator
- University of BergenStudy chair
- University of MontpellierStudy chair
- University of BergenCollaborator
- European and Developing Countries Clinical Trials Partnership (EDCTP)Collaborator
- Government of NorwayCollaborator
- Government of SwedenCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.